CSBio CSBio

X
[{"orgOrder":0,"company":"Rappta Therapeutics","sponsor":"Novo Seeds","pharmaFlowCategory":"D","amount":"$10.6 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Seeds Co-Leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A Drugs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"FINLAND","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Rappta Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Rappta has developed proprietary tools and a unique understanding of PP2A which allows it to therapeutically reactivate PP2A.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Novo Seeds

            Deal Size: $10.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing October 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY